Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
35results about How to "Modulating level" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Electrical stimulation of the sympathetic nerve chain
InactiveUS20050065562A1Convenient treatmentModulating levelSpinal electrodesExternal electrodesSympathetic nerveSacral sympathetic chain
The present invention provides a method of affecting physiological disorders by stimulating a specific location along the sympathetic nerve chain. Preferably, the present invention provides a method of affecting a variety of physiological disorders or pathological conditions by placing an electrode adjacent to or in communication with at least one ganglion along the sympathetic nerve chain and stimulating the at least one ganglion until the physiological disorder or pathological condition has been affected.
Owner:THE CLEVELAND CLINIC FOUND
Indazole compounds, compositions thereof and methods of treatment therewith
This invention is generally directed to the use of Indazole Compounds for treating or preventing diseases associated with protein kinases, including tyrosine kinases, such as proliferative diseases, inflammatory diseases, abnormal angiogenesis and diseases related thereto, atherosclerosis, macular degeneration, diabetes, obesity, pain and others. The methods comprise the administration to a patient in need thereof of an effective amount of an indazole compound that inhibits, modulates or regulates tyrosine kinase signal transduction. Novel indazole compounds or pharmaceutically acceptable salt thereof are presented herein.
Owner:SIGNAL PHARMA LLC
Dynamically-controlled cushioning system for an article of footwear
An article of footwear with a dynamically-controlled cushioning system is disclosed. The cushioning system includes a sealed, fluid-filled bladder formed with a plurality of separate cushioning chambers, and a control system. The control system, which includes a CPU, pressure sensors and valves, controls fluid communication between the chambers to dynamically adjust the pressure in the cushioning chambers for various conditions such as the activity that the footwear is used in, the weight of the individual and the individual's running style. Certain adjustments can be made while the footwear is in use.
Owner:NIKE INC
Mif modulators
Owner:YALE UNIV
Methods for Treating Spinal Muscular Atrophy Using Tetracycline Compounds
Methods for using tetracycline compounds for the treatment of spinal muscular atrophy are described.
Owner:MINTZ LEVIN COHN FERRIS GLOVSKY & POPEO PC
Indazole compounds and methods of use thereof
InactiveUS20060004043A1Modulating levelUseful in treatmentAntibacterial agentsBiocideAutoimmune conditionProtein kinase A signaling
This invention is directed to Indazole Compounds or pharmaceutically acceptable salts, solvates and hydrates thereof. The Indazole Compounds have utility in the treatment or prevention of a wide range of diseases and disorders that are responsive to the inhibition, modulation or regulation of kinases, such as inflammatory diseases, abnormal angiogenesis and diseases related thereto, cancer, atherosclerosis, a cardiovascular disease, a renal disease, an autoimmune condition, macular degeneration, disease-related wasting, an asbestos-related condition, pulmonary hypertension, diabetes, obesity, pain and others. Thus, methods of treating or preventing such diseases and disorders are also disclosed, as are pharmaceutical compositions comprising one or more of the Indazole Compounds. This invention is based, in part, upon the discovery of a novel class of 5-triazolyl substituted indazole molecules that have potent activity with respect to the modulation of protein kinases. Thus, the invention encompasses orally active molecules as well as parenterally active molecules which can be used at lower doses or serum concentrations for treating diseses or disorders associated with protein kinase signal transduction.
Owner:BHAGWAT SHRIPAD S +10
Method for enhancing production of isoprenoid compounds
ActiveUS20060079476A1Modulating levelToxic levelGenetic material ingredientsOxidoreductasesENCODEMevalonate pathway
The present invention provides methods of producing an isoprenoid or an isoprenoid precursor in a genetically modified host cell. The methods generally involve modulating the level of hydroxymethylglutaryl-CoA (HMG-CoA) in the cell, such that the level of HMG-CoA is not toxic to the cell and / or does not substantially inhibit cell growth, but is maintained at a level that provides for high-level production of mevalonate, IPP, and other downstream products of an isoprenoid or isoprenoid pathway, e.g., polyprenyl diphosphates and isoprenoid compounds. The present invention further provides genetically modified host cells that are suitable for use in a subject method. The present invention further provides recombinant nucleic acid constructs for use in generating a subject genetically modified host cell, including recombinant nucleic acid constructs comprising nucleotide sequences encoding one or more mevalonate pathway enzymes, and recombinant vectors (e.g., recombinant expression vectors) comprising same. The present invention further provides methods for identifying nucleic acids that encode HMG-CoA reductase (HMGR) variants that provide for relief of HMG-CoA accumulation-induced toxicity. The present invention further provides methods for identifying agents that reduce intracellular accumulation of HMG-CoA.
Owner:RGT UNIV OF CALIFORNIA
Antibodies Specific For Soluble Amyloid Beta Peptide Protofibrils and Uses Thereof
ActiveUS20090155246A1Avoid side effectsModulating levelNervous disorderMicrobiological testing/measurementAntigenAmyloid beta
The invention pertains to the development of antibodies that specifically bind amyloid beta protein (Abeta) in its protofibril conformation. The invention also comprises methods of using anti-Abeta protofibril antibodies to diagnose or treat Alzheimer's disease, Down's syndrome Lewybody dementia, vascular dementia, and other neurodegenerative disorders. Furthermore, the invention pertains to the use of anti-Abeta protofibril antibodies to screen and identify substances that will modulate protofibril activity or formation in vitro or in vivo. The invention also pertains to methods for synthesising pure Abeta protofibril antigens as well as to a method for stabilising Abeta protofibrils antigens as well as to a method for stabilising Abeta protofibrils.
Owner:BIOARCTIC NEUROSCI AB
Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof
ActiveUS8106164B2Avoid side effectsModulating levelNervous disorderMicrobiological testing/measurementAntigenAmyloid beta
Owner:BIOARCTIC NEUROSCI AB
Agent for treating disease
InactiveUS20110059084A1Easy to manageReduce dosageNervous disorderAntipyreticAutoimmune diseaseCD4 antigen
The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 0.2 mg to 30 mg.
Owner:BIOTEST SERUM INST GMBH
Mif modulators
Owner:YALE UNIV
Methods of treating disease with nitric oxide (NO)-releasing polymers and soluble no-releasing nitrosamines
The invention provides NO-releasing polymers and low molecular weight NO-releasing compounds which may be used to for the treatment of medical conditions associated with NO-deficiency. The NO-releasing polymers or the low molecular weight NO-releasing compounds may also be incorporated into medical devices. The invention further provides methods of controlled release of NO for the treatment of diseases and disorders associated with NO-deficiency, wherein the treatment includes systemic or local administration of the NO-releasing polymers or the low molecular weight NO-releasing compounds.
Owner:CENTRAL MICHIGAN UNIVERSITY
Mif modulators
Owner:YALE UNIV
Apparatus and method for allocating resources in wireless communication system
ActiveUS20190208510A1Increase modulation code rate levelBig amount of dataError prevention/detection by using return channelPower managementTransceiverResource block
A pre-5th-Generation (5G) or 5G communication system is provided for supporting higher data rates than in 4th-Generation system. An apparatus of a base station includes: at least one transceiver and at least one processor operatively connected to the transceiver. The transceiver receives channel quality information from a terminal. The processor obtains a first modulation and coding scheme (MCS) level and a number of first resource blocks based on the channel quality information, determines a power boosting value for applying a second MCS level indicating a higher modulation order or a higher code rate than the first MCS level, obtains, based on the power boosting value, a number of second resource blocks corresponding to a transport block size (TBS) value greater than a TBS value corresponding to the number of the first resource blocks in the first MCS level and transmits downlink data based on these determinations.
Owner:SAMSUNG ELECTRONICS CO LTD
Use of muramyl dipeptide (MDP) for treating inflammation
ActiveUS20100292153A1Reducing symptom characteristicInhibit inflammationAntipyreticDigestive systemMedicineMuramyl dipeptide
The present invention provides a method of treating or preventing inflammation in a subject comprising administering to the subject an effective amount of a muramyl dipeptide (MDP).
Owner:UNITED STATES OF AMERICA
Methods and compositions for treating Parkinson's disease
InactiveUS20050070493A1Lower Level RequirementsIncrease in tyrosine hydroxylase activityNervous disorderPeptide/protein ingredientsMedicineDopaminergic
The present invention relates to novel methods and compositions for gene therapy. The invention also provides methods for treating diseases or disorders of the central nervous system associated with dopaminergic hypoactivity, disease, injury or chemical lesioning, including Parkinson's disease, manic depression, and schizophrenia.
Owner:BAYLOR COLLEGE OF MEDICINE +1
Immunological modulation of insulin-like growth factor 1 for cancer prevention/treatment and prolonging longevity
ActiveUS7749966B2Simple and safe and effectiveReduce morbidityAntibacterial agentsPeptide/protein ingredientsCancer preventionInsulin-like growth factor
Owner:RASO VICTOR DR
Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals
InactiveUS7001617B2Coloring be generatePromote wound healingSuture equipmentsHeavy metal active ingredientsMetalloproteinaseInflammatory cell
The invention relates to a method to induce apoptosis and to inhibit matrix metalloproteinases in a disease condition in a human or animal by contacting hyperplastic tissue, tumor tissue, or a cancerous lesion with one or more antimicrobial metals, preferably formed with atomic disorder, and preferably in a nanocrystalline form. In another aspect of the invention, there is provided a method of preventing excessive release of matrix metalloproteinases from an inflammatory cell in a disease condition in a human or an animal by contacting the cell with a therapeutically effective amount of a noble metal in a crystalline form characterized by atomic disorder, or with a solution derived therefrom to provide a modulatory effect on one or more matrix metalloproteinases, wherein the one or more noble metals is formed with atomic disorder, and preferably in a nanocrystalline form. The nanocrystalline antimicrobial or noble metal of choice may be used in the form of a nanocrystalline coating of one or more antimicrobial or noble metals, a nanocrystalline powder of one or more antimicrobial or noble metals, or a solution containing dissolved species from a nanocrystalline powder or coating of one or more antimicrobial or noble metals.
Owner:NUCRYST PHARMA
Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof
ActiveUS20120230912A1Avoid side effectsModulating levelNervous disorderImmunoglobulins against animals/humansAmyloid betaMonoclonal antibody
The invention pertains to a method of measuring Aβ protofibrils in a sample. The method includes the steps of (a) providing a labeled monoclonal antibody or fragment thereof that binds wildtype Aβ 42 / 40 protofibril and Aβ42 / 40 Arc protofibril and has no or little cross-reactivity to Aβ 42 / 40 monomers with an agent that generates a measurable signal, (b) contacting said labeled antibody or fragment thereof with the fluid or tissue having or suspected of comprising Aβ protofibrils, and (c) measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent.
Owner:BIOARCTIC NEUROSCI AB
Methods of Modulating Inflammation in Preterm Infants Using Carotenoids
ActiveUS20110136734A1Reduced plasma concentrationModulating levelBiocidePeptide/protein ingredientsBeta-CaroteneLutein
The present disclosure relates to preterm infant formulas comprising lutein, lycopene, and beta-carotene, and the use of the preterm infant formulas to modulate inflammation, such as skin inflammation, in preterm infants. Also disclosed are methods of modulating the level of C-reactive protein in a preterm infant using preterm infant formulas comprising mixtures of carotenoids.
Owner:ABBOTT LAB INC
FHOS-interacting proteins and use thereof
InactiveUS20050100966A1Easy to prepareEnhancing and stabilizing interactionPeptide librariesHydrolasesDiseaseAssay
Protein complexes are provided comprising FHOS and one or more proteins selected from the group consisting of GROUP1. Methods of using the protein complexes in diagnosing diseases and disorders are also provided. In addition, the protein complexes are also useful in screening assays for identifying compounds effective in treating and / or preventing diseases and disorders associated with FHOS and its interactors.
Owner:HITACHI PLANT TECH LTD +1
Method for treating psoriasis
InactiveUS9334325B2Improve responseModulating levelNervous disorderAntipyreticRegulatory T cellAutoimmune condition
The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 0.2 mg to 30 mg.
Owner:BIOTEST SERUM INST GMBH
Immunomodulation by controlling elr+ proinflammatory chemokine levels with the long non-coding RNA umlilo
InactiveUS20170349898A1Reduce productionAdjustmentAntipyreticAnalgesicsImmunomodulationsLong non-coding RNA
The present invention relates to methods for modulating the production of ELR+ proinflammatory chemokines in a subject or a cell using either UMLILO IncRNA inhibitors to decrease production of ELR+ proinflammatory cytokines or using UMLILO IncRNA's to increase the production of ELR+ proinflammatory cytokines. The invention also provides for the use of UMLILO IncRNA inhibitors or UMLILO IncRNA's to modulate the expression of ERL+ proinflammatory cytokines.
Owner:CSIR
Metabolic transistor in bacteria
The disclosure relates to a metabolic transistor in bacteria where a competitive pathway is introduced to compete with a product pathway for available carbon so as to control the carbon flux in the bacteria.
Owner:WILLIAM MARSH RICE UNVERSITY
Treatment of disorders associated with inflammation
ActiveUS20210093862A1Minimized surgical injuryMinimize damageSpinal electrodesImplantable neurostimulatorsDiseaseNerve supply
Stimulation of neural activity in a nerve supplying the spleen, wherein the nerve is adjacent to the splenic artery at a position where the splenic artery is not in direct contact with the pancreas, can modulate pro- and anti-inflammatory molecules levels, thereby reducing inflammation and providing ways of treating disorders, such as disorders associated with inflammation. The invention provides improved ways of reducing inflammation with minimized off-target effects, in particular surgical trauma.
Owner:GALVANI BIOELECTRONICS LTD
Reverse targeting lipid vesicle
InactiveUS20090317455A1Modulating levelSimple wayAntibacterial agentsSenses disorderAntigenAutoimmune condition
The present invention provides an immunomodulating agent and a therapeutic agent for a immune disease, which comprise a lipid vesicle encapsulating a drug capable of suppressing or damaging an immunocyte that expresses or binds to an antibody, the lipid vesicle having an antigen for the antibody bound to the outer surface thereof. Hence, there is provided means for effectively treating an immune disease such as an allergic diseases or an autoimmune disease.
Owner:OKU NAOTO +1
Compound for increasing kinase active and application thereof
The compound of Formula (I), pharmaceutically acceptable salts thereof, solvates thereof, chelates thereof, non-covalent complexes thereof or produgs of compounds mentioned above or the mixture of any form above mentioned are provided. The use of the compounds in manufacturing a medicament for the treatment and / or prevention of diabetes, obesity and related disorders.
Owner:FUJIAN HAIXI PHARMA +1
Apparatus and method for allocating resources in wireless communication system
ActiveUS10869308B2Big amount of dataModulating levelError prevention/detection by using return channelPower managementTransceiverCommunications system
A pre-5th-Generation (5G) or 5G communication system is provided for supporting higher data rates than in 4th-Generation system. An apparatus of a base station includes: at least one transceiver and at least one processor operatively connected to the transceiver. The transceiver receives channel quality information from a terminal. The processor obtains a first modulation and coding scheme (MCS) level and a number of first resource blocks based on the channel quality information, determines a power boosting value for applying a second MCS level indicating a higher modulation order or a higher code rate than the first MCS level, obtains, based on the power boosting value, a number of second resource blocks corresponding to a transport block size (TBS) value greater than a TBS value corresponding to the number of the first resource blocks in the first MCS level and transmits downlink data based on these determinations.
Owner:SAMSUNG ELECTRONICS CO LTD
Novel card proteins involved in cell death regulation
InactiveUS20040253231A1Effectively alterIncrease and decrease levelOrganic active ingredientsFungiNucleotide sequencingAntibody
The present invention provides NB-ARC and CARD-containing proteins (NACs), nucleic acid molecules encoding NACs and antibodies specific for at least one NAC. The invention further provides chimeric NAC proteins. The invention also provides screening assays for identifying an agent that can effectively alter the association of a NAC with a NAC-associated protein. The invention further provides methods of modulating apoptosis in a cell by introducing into the cell a nucleic acid molecule encoding a NAC or an antisense nucleotide sequence. The invention also provides a method of using a reagent that can specifically bind to a NAC to diagnose a pathology that is characterized by an increased or decreased level of apoptosis in a cell.
Owner:THE BURNHAM INST
Metabolic transistor in bacteria
ActiveUS20170009241A1Modulating levelIncrease overall carbon flowHydrolasesTransferasesYeastBiotechnology
The disclosure relates to a metabolic transistor in microbes such as bacteria and yeast where a competitive pathway is introduced to compete with a product pathway for available carbon so as to control the carbon flux in the microbe.
Owner:RICE UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com